A genetically modified stem cell therapy for Diffuse Large B-Cell Lymphoma (DLBCL) has been approved by the FDA. Researchers at the Abramson Cancer Center, in collaboration with Novartis, have successfully administered a CAR-T Cell therapy, called Kymriah, for the most common type of non-Hodgkin Lymphoma. DLBCL is a fast growing cancer that affects B lymphocytes, which are responsible for producing antibodies that help fight infections in the body. This groundbreaking treatment involves obtaining autologous (the patient’s own) T cells, which are a more specialized type of stem cell, and genetically engineering the cells to track down and destroy cancerous cells.
The study’s findings showed an overall response rate of 50% for patients, many of whom were in Stage III and IV of DLBCL. 30% of patients exhibited a complete response to the treatment and an additional 18% exhibited a partial response. “The approval of Kymriah for patients with relapsed and refractory DLBCL is a major step forward to continue improving treatment outcomes for these patients. It is the second CAR-T cell to be approved, based on high response rates in patient populations with unmet medical needs,” comments Dr. Anas Younes, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center.
Novartis' innovative research demonstrates the integral role stem cells are playing in cutting edge medical care options. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies in the near future. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.